X

Trial Profile

A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERAS 007 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Asana BioSciences

Most Recent Events

22 Oct 2020 According to an Asana Biosciences media release, data from this study will be presented 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) to be held on October 24-25, 2020.
07 Jul 2020 Status changed from active, no longer recruiting to completed.
06 Dec 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com